Several VisionGate team leaders were instrumental in the development and commercialization of the Class III PMA FDA-approval of NeoPath, Inc. (now part of BD Diagnostics), one of the few devices approved for the early detection (primary screening) of cervical cancer.
VisionGate’s senior management team is described more fully below.
Alan C. Nelson, PhD
Founder, Chairman and CEO
Dr. Alan Nelson, Founder, Chairman and CEO of VisionGate, has overall responsibility for the strategic direction and long-term vision of the company. Dr. Nelson, prior Executive Director, The Biodesign Institute at Arizona State University, is now leading the Predictive Health Analytics Initiative (PHAIT3). Dr. Nelson has also been appointed in two faculty positions; Professor of Bioengineering and Professor of Physics at Arizona State University. Prior to VisionGate, Dr. Nelson was the founder, President and CEO of NeoPath where he developed the world’s first automated cytology platform. Neopath won landmark FDA approval in 1995 and introduced the AutoPap, a fully automated instrument for primary screening of Pap smears. After a successful Initial Public Offering in 1996, Neopath was sold to Becton Dickinson in 2000. Before coming to ASU, Dr. Nelson was also a tenured Associate Professor and Director of the Center for Imaging Systems Optimization and the Medical Imaging Graduate Program at the University of Washington. Additionally, he was an Associate Professor with joint appointments at MIT and Harvard where he held the W.M. Keck Foundation endowed chair and directed the Radiological Sciences Program. Dr. Nelson holds over thirty US patents and has over 100 peer reviewed publications in the field of biomedical imaging. He received his PhD in Biophysics from the University of California, Berkeley.
Scarlett Spring, MBA
Scarlett serves as President managing strategic initiatives, investor relations and day to day operations of VisionGate. Scarlett, a prior executive in major pharma with over two decades of national sales and marketing experience of blockbuster drugs. Before joining VisionGate, Scarlett served 2½ years as COO and Executive Vice President of Business Development for the Greater Phoenix Economic Council where she had profit and loss responsibility for a $4.9M budget and led a 27-person team. Her functions included investor relations, building collaborative relationships among the 19 member municipalities, and crafting strategies for the healthcare/biomedical industry.
Scarlett has extensive prior experience in the oncology field. She spent 19 years at AstraZeneca where she was responsible for the management of $1.8B in product sales and a 375-person sales team as the company’s national sales director for oncology and urology divisions. Over her tenure, she led numerous change-management initiatives resulting in the strongest years of oncology performance—driving key oncology brand growth, including lung cancer chemotherapy drugs, 50%, 45%, 42% and 29% respectively over a four year timeframe. She also has experience in the GI area with the launch of Prilosec and Nexium for reflux disease (GERD) while building her career, starting at the field sales representative level and rising through several marketing and sales roles, ultimately with responsibility over a 500+ person sales team including eight regional sales directors and 64 district managers.
Scarlett has a BBA in marketing from the University of Texas at Austin and an Executive MBA from Pepperdine University. She volunteers each year during the Houston Livestock Show and Rodeo, the largest provider of scholarships for Texas youth.
Michael G. Meyer, MS
Chief Technical Officer
As CTO, Michael coordinates efforts among the various technical groups within VisionGate and provides final technical arbitration. Michael also supervises development of Cell-CT image processing and training of algorithms to compute VisionGate test results and the development of technical strategies to validate them. Between 1992 and late 2004 he was a Research Scientist for TriPath Imaging, Inc. (formerly NeoPath), where he supervised a variety of efforts to develop algorithms to detect rarely occurring cervical neoplasms and their precursors on Pap-smear slides. Prior to work at TriPath he was employed at IBM in Rochester, MN, where his career focused on magnetic recording and signal processing research, mechanical reliability, associated with the design of hard disk files. Michael earned his Master’s degree in EE in 1992 from the University of Washington.
Thomas Neumann, MD
Vice President for Medical Sciences
Dr. Thomas Neumann leads VisionGate’s clinical studies to validate the diagnostic performance of the Cell-CT system. As a physician and researcher, he has longstanding interest in cancer research and tissue engineering where he has been highly inventive. Prior to joining VisionGate, Dr. Neumann was a Research Assistant Professor at the University of Washington. He is Principal Investigator of several NIH grants awarded to VisionGate, including a $2.6 million ARRA grant for advancing the Cell-CT technology into a high throughput diagnostic platform.
Jon W. Hayenga, MS
Vice President for Advanced Product Development
Jon has 29 years of product development experience, 22 of it in FDA-regulated industry. He has held senior engineering and management roles in previous start up biomedical technology companies, including NeoPath where he delivered emerging complex technology products. Before joining VisionGate, Jon was Director of Engineering at Micronics where he developed patented technologies utilizing instrumentation and micro-fluidics solutions for the biotech industry. He holds over 30 patents and contributes at the theoretical level as well as the applied level. Jon holds a Master’s degree in EE from the University of Idaho.